Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma

Vanessa Klapp, Lorenzo Galluzzi*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review


Depending on intensity and duration, STING1 (stimulator of interferon response cGAMP interactor 1) signaling can restrain or promote tumor progression via both cancer cell-intrinsic and -extrinsic pathways. Bruand et al. recently identified a novel STING1-driven immunosuppressive pathway that can be targeted toward superior disease control in preclinical models of homologous recombination deficient (HRD) ovarian carcinoma.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalTrends in Cancer
Issue number1
Publication statusPublished - Jan 2022
Externally publishedYes


  • autophagy
  • CGAS
  • immune checkpoint inhibitors
  • PARP inhibitors
  • venetoclax


Dive into the research topics of 'Multimodal immunostimulation to control BRCA1-defective ovarian carcinoma'. Together they form a unique fingerprint.

Cite this